Amgen Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMGN research report →
About the company
Amgen Inc. , established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience.
- CEO
- Robert A. Bradway
- IPO
- 1983
- Employees
- 28,000
- HQ
- Thousand Oaks, CA, US
Price Chart
- Market Cap
- $187.73B
- P/E
- 24.08
- P/S
- 5.04
- P/B
- 20.44
- EV/EBITDA
- 13.96
- Div Yield
- 2.82%
- Gross Margin
- 71.46%
- Op Margin
- 31.63%
- Net Margin
- 20.95%
- ROE
- 89.41%
- ROIC
- 13.85%
- Revenue
- $36.74B · 9.92%
- Net Income
- $7.71B · 88.53%
- EPS
- $14.33 · 88.06%
- Op Income
- $10.68B
- FCF YoY
- -22.07%
- 52W High
- $391.29
- 52W Low
- $267.83
- 50D MA
- $340.36
- 200D MA
- $331.04
- Beta
- 0.42
- Avg Volume
- 2.73M
Get TickerSpark's AI analysis on AMGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 26 | MILES AMY E | other | 665 |
| May 19, 26 | Kullman Ellen Jamison | other | 665 |
| May 19, 26 | Klotman Mary E. | other | 665 |
| May 19, 26 | Jacks Tyler | other | 665 |
| May 19, 26 | ISHRAK OMAR | other | 665 |
| May 19, 26 | HOLLEY CHARLES M | other | 665 |
| May 19, 26 | Garland Greg C. | other | 665 |
| May 19, 26 | ECKERT ROBERT | other | 665 |
| May 19, 26 | Druker Brian | other | 665 |
| May 19, 26 | Drake Michael V | other | 665 |
Our AMGN coverage
Recent articles, reports, and earnings notes.
Amgen (AMGN): Growth Broadens Beyond Patent Cliffs
Amgen is growing through patent expirations with broad-based momentum across Repatha, rare disease, oncology, and biosimilars. The stock looks like a Buy, though valuation already reflects much of the resilience.
Kardigan, IPO: What to Know Before It Lists
Kardigan is expected to list on NASDAQ on 2026-06-18, with shares priced at $14.00 to $16.00. The IPO centers on a clinical-stage cardiovascular pipeline and a balance sheet that still needs capital to keep advancing. Watch whether investors focus on the three lead programs or the company’s going-concern warning.
The GLP-1 trade is becoming a market-share war, not a rising-tide story
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Want a deeper read on AMGN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.